
    
      This is a randomized, single-blind,phase II clinical trial.

      At least 28 subjects who are with a clinical diagnosis of knee osteoarthritis cartilage
      defects will be randomly distributed 1:1 to the treatment group or the control group after
      signing the ICF and screening tests.The treatment will accept ReJoinTM at the first and
      fourth week,and Sodium Hyaluronate Injection at the second and third week.The control group
      will accept Sodium Hyaluronate Injection weekly ,and four injections in total.The duration of
      the therapy is 48 weeks.

      In addition, external control will be added if necessary.
    
  